Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 48

1.

Ulva lactuca polysaccharides prevent Wistar rat breast carcinogenesis through the augmentation of apoptosis, enhancement of antioxidant defense system, and suppression of inflammation.

Abd-Ellatef GF, Ahmed OM, Abdel-Reheim ES, Abdel-Hamid AZ.

Breast Cancer (Dove Med Press). 2017 Feb 27;9:67-83. doi: 10.2147/BCTT.S125165. eCollection 2017 Feb 27.

2.

Bcl-2 expression is a poor predictor for hepatocellular carcinoma prognosis of andropause-age patients.

Zhang XF, Yang X, Jia HL, Zhu WW, Lu L, Shi W, Zhang H, Chen JH, Tao YF, Wang ZX, Yang J, Wang LX, Lu M, Zheng Y, Zhao J, Dong QZ, Qin LX.

Cancer Biol Med. 2016 Dec;13(4):459-468. doi: 10.20892/j.issn.2095-3941.2016.0077.

3.

BCL2 as a Subtype-Specific Prognostic Marker for Breast Cancer.

Eom YH, Kim HS, Lee A, Song BJ, Chae BJ.

J Breast Cancer. 2016 Sep;19(3):252-260. Epub 2016 Sep 23.

4.

Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes.

Dai X, Xiang L, Li T, Bai Z.

J Cancer. 2016 Jun 23;7(10):1281-94. doi: 10.7150/jca.13141. eCollection 2016 Jun 23. Review.

5.

S6K1 inhibition enhances the apoptotic cell death of breast cancer cells in response to Bcl-2/Bcl-xL inhibition by the downregulation of survivin.

Park JA, Jin HO, Lee HN, Kim JH, Park IC, Noh WC, Chang YH, Hong YJ, Kim KC, Lee JK.

Oncol Lett. 2015 Aug;10(2):829-834. Epub 2015 Jun 11.

6.

BCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of Apoptosis.

Gibson CJ, Davids MS.

Clin Cancer Res. 2015 Nov 15;21(22):5021-9. doi: 10.1158/1078-0432.CCR-15-0364. Review.

7.

Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy.

Honma N, Horii R, Ito Y, Saji S, Younes M, Iwase T, Akiyama F.

BMC Cancer. 2015 Oct 15;15:698. doi: 10.1186/s12885-015-1686-y.

8.

Expression of alpha B crystallin and BCL2 in patients with infiltrating ductal carcinoma.

Kim MS, Lee HW, Jun SY, Lee EH.

Int J Clin Exp Pathol. 2015 Aug 1;8(8):8842-56. eCollection 2015 Aug 1.

9.

An Epigenetic Pathway Regulates Sensitivity of Breast Cancer Cells to HER2 Inhibition via FOXO/c-Myc Axis.

Matkar S, Sharma P, Gao S, Gurung B, Katona BW, Liao J, Muhammad AB, Kong XC, Wang L, Jin G, Dang CV, Hua X.

Cancer Cell. 2015 Oct 12;28(4):472-85. doi: 10.1016/j.ccell.2015.09.005.

10.

Comprehensive prognostic analysis in breast cancer integrating clinical, tumoral, micro-environmental and immunohistochemical criteria.

de Mascarel I, Debled M, Brouste V, Mauriac L, Sierankowski G, Velasco V, Croce S, Chibon F, Boudeau J, Debant A, MacGrogan G.

Springerplus. 2015 Sep 21;4:528. doi: 10.1186/s40064-015-1297-8. eCollection 2015 Sep 21.

11.

Immune microenvironment as a factor of breast cancer progression.

Romaniuk A, Lуndіn M.

Diagn Pathol. 2015 Jun 26;10:79. doi: 10.1186/s13000-015-0316-y.

12.

The role of Nanog expression in tamoxifen-resistant breast cancer cells.

Arif K, Hussain I, Rea C, El-Sheemy M.

Onco Targets Ther. 2015 Jun 3;8:1327-34. doi: 10.2147/OTT.S67835. eCollection 2015 Jun 3.

13.

Decline in Antigenicity of Tumor Markers by Storage Time Using Pathology Sections Cut From Tissue Microarrays.

Blows FM, Ali HR, Dawson SJ, Le Quesne J, Provenzano E, Caldas C, Pharoah PD.

Appl Immunohistochem Mol Morphol. 2016 Mar;24(3):221-6. doi: 10.1097/PAI.0000000000000172. Erratum in: Appl Immunohistochem Mol Morphol. 2016 May-Jun;24(5):382.

14.

Patient-derived xenograft models of breast cancer and their predictive power.

Whittle JR, Lewis MT, Lindeman GJ, Visvader JE.

Breast Cancer Res. 2015 Feb 10;17:17. doi: 10.1186/s13058-015-0523-1. Review.

15.

Regulation of anti-apoptotic signaling by Kruppel-like factors 4 and 5 mediates lapatinib resistance in breast cancer.

Farrugia MK, Sharma SB, Lin CC, McLaughlin SL, Vanderbilt DB, Ammer AG, Salkeni MA, Stoilov P, Agazie YM, Creighton CJ, Ruppert JM.

Cell Death Dis. 2015 Mar 19;6:e1699. doi: 10.1038/cddis.2015.65.

16.

How cell death shapes cancer.

Labi V, Erlacher M.

Cell Death Dis. 2015 Mar 5;6:e1675. doi: 10.1038/cddis.2015.20. Review.

17.

Trefoil factor 3 promotes metastatic seeding and predicts poor survival outcome of patients with mammary carcinoma.

Pandey V, Wu ZS, Zhang M, Li R, Zhang J, Zhu T, Lobie PE.

Breast Cancer Res. 2014 Sep 30;16(5):429. doi: 10.1186/s13058-014-0429-3.

18.

Significance of immunohistochemistry in breast cancer.

Zaha DC.

World J Clin Oncol. 2014 Aug 10;5(3):382-92. doi: 10.5306/wjco.v5.i3.382. Review.

19.

Profiling of luteal transcriptome during prostaglandin F2-alpha treatment in buffalo cows: analysis of signaling pathways associated with luteolysis.

Shah KB, Tripathy S, Suganthi H, Rudraiah M.

PLoS One. 2014 Aug 7;9(8):e104127. doi: 10.1371/journal.pone.0104127. eCollection 2014 Aug 7.

20.

Artemin, a member of the glial cell line-derived neurotrophic factor family of ligands, is HER2-regulated and mediates acquired trastuzumab resistance by promoting cancer stem cell-like behavior in mammary carcinoma cells.

Ding K, Banerjee A, Tan S, Zhao J, Zhuang Q, Li R, Qian P, Liu S, Wu ZS, Lobie PE, Zhu T.

J Biol Chem. 2014 Jun 6;289(23):16057-71. doi: 10.1074/jbc.M113.529552. Epub 2014 Apr 15.

Supplemental Content

Support Center